title: Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.
abstract: Aggressive T cell lymphomas are a subgroup of lymphomas with a particularly poor prognosis. This is especially true for patients with recurrent or refractory disease, who typically have limited response to salvage therapy and extremely poor overall survival. For this reason, there is a strong need to develop potentially active drugs for these malignancies. Pralatrexate is a novel antifolate designed to have high affinity for reduced folate carrier type 1. Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against T cell lymphomas. The dose-limiting toxicity for pralatrexate is mucositis, which can be abrogated with folic acid and vitamin B12 supplementation. Pralatrexate is the first single agent approved for the treatment of patients with relapsed or refractory peripheral T cell lymphoma. This approval was based on an overall objective response rate observed in the pivotal study. The overall response rate was 29%, with a median duration of 10.1 months. This article reviews the biochemistry, preclinical experience, metabolism, and pharmacokinetics of pralatrexate, including the clinical experience with this agent in lymphoma. Future areas of development are now focused on identifying synergistic combinations of pralatrexate with other agents and the evaluation of predictive markers for clinical benefit.
authors.affiliation: Oncohematology Service, Hospital Costa del Sol, Marbella, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Casanova
authors.forename: A
authors.initials: A
authors.lastname: Medina-Pérez
authors.forename: M
authors.initials: M
authors.lastname: Moreno-Beltran
authors.forename: M
authors.initials: M
authors.lastname: Mata-Vazquez
authors.forename: A
authors.initials: A
authors.lastname: Rueda
references.citation: Blood. 1994 Sep 1;84(5):1361-92
references.pmid: 8068936
references.citation: Clin Cancer Res. 2000 Sep;6(9):3493-8
references.pmid: 10999734
references.citation: Blood. 2011 Jun 23;117(25):6756-67
references.pmid: 21493798
references.citation: Curr Opin Oncol. 2006 Nov;18(6):591-7
references.pmid: 16988580
references.citation: Br J Cancer. 2011 Jan 18;104(2):272-80
references.pmid: 21179031
references.citation: J Clin Invest. 1979 Sep;64(3):788-97
references.pmid: 288743
references.citation: Blood. 1997 Jun 1;89(11):3909-18
references.pmid: 9166827
references.citation: Best Pract Res Clin Haematol. 2002 Dec;15(4):695-711
references.pmid: 12617871
references.citation: Clin Pharmacol Ther. 2009 Aug;86(2):190-6
references.pmid: 19474785
references.citation: Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9
references.pmid: 19221750
references.citation: Cancer Metastasis Rev. 2007 Mar;26(1):153-81
references.pmid: 17333344
references.citation: Br J Haematol. 2007 Nov;139(3):425-8
references.pmid: 17910632
references.citation: IDrugs. 2008 Jul;11(7):508-21
references.pmid: 18600598
references.citation: Clin Cancer Res. 2010 Oct 15;16(20):4921-7
references.pmid: 20739433
references.citation: Ann Oncol. 2002 Jan;13(1):140-9
references.pmid: 11863096
references.citation: Br J Cancer. 1993 Oct;68(4):767-74
references.pmid: 8398705
references.citation: Ann Oncol. 1990;1(1):45-50
references.pmid: 1706610
references.citation: Ann Oncol. 1998 Aug;9(8):849-55
references.pmid: 9789607
references.citation: Leuk Lymphoma. 2008 Mar;49(3):410-26
references.pmid: 18297517
references.citation: Ann Oncol. 1998 Jul;9(7):717-20
references.pmid: 9739436
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1182-9
references.pmid: 21245435
references.citation: Ann Oncol. 1998 Aug;9(8):835-43
references.pmid: 9789605
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):924-32
references.pmid: 16467107
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references.pmid: 18626005
references.citation: Curr Treat Options Oncol. 2004 Aug;5(4):289-303
references.pmid: 15233906
references.citation: Anticancer Agents Med Chem. 2008 Feb;8(2):205-31
references.pmid: 18288923
references.citation: Leuk Lymphoma. 2003 Jun;44(6):1027-35
references.pmid: 12854905
references.citation: J Am Acad Dermatol. 2008 Mar;58(3):480-4
references.pmid: 18280345
references.citation: Cancer Chemother Pharmacol. 1984;12(1):18-25
references.pmid: 6690069
references.citation: J Med Chem. 1993 Jul 23;36(15):2228-31
references.pmid: 8340923